Organisation paid for research Program year 2022 Source: CMS Open Payments

VRC Long Island Vitreoretinal

Neither a doctor nor a teaching hospital

Research payments

$484,927

36 payments

Through program year 2022, VRC Long Island Vitreoretinal is reported as receiving $484,927 in research payments, across 36 payments.

By program year

1 row

Year	Kind	Amount	Payments
2022	Research	$484,927	36

Breakdown

Who paid Research payments · program year 2022

Genentech, Inc. $484,927 36 payments

Studies the money was for Research payments · program year 2022

A Phase III Study to Evaluate Faricimab in Patients With Central Retinal Vein Occlusion $112,467 5 payments
A Phase III Study to Evaluate Faricimab in Patients With Branch Retinal Vein Occlusion $93,294 6 payments
Open Label Extension Study to Evaluate the Long Term Safety of Faricimab in Patients With Namd $80,119 4 payments
Faricimab Dme Long Term Extension Rhone X $72,247 9 payments
Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $48,579 5 payments
Va2 Phiii $39,386 1 payment
Va2 Phiii Yosemite $17,636 1 payment
Port Delivery System of Ranibizumab Extension Study $12,887 4 payments
Port Delivery System for Ranibizumab $8,312 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.